lateral canthal drooping thread lifting
Conditions
Interventions
Participants will undergo treatment with multiple bidirectional Newton cog polydioxanone (PDO) threads for lateral canthal elevation. Local anesthesia will be administered prior to the procedure in al
Experimental Device
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
25 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Participants aged 25 to 60 years, including both males and females. 2. Participants with lateral canthal drooping who do not have indications for surgical intervention, such as eyelid ptosis, or participants with normal lateral canthal position who wish to enhance the shape of the lateral canthus for a sharper appearance.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women. 2. Participants with underlying medical conditions, including platelet disorders, coagulation abnormalities, anemia, liver disease, malignancy, or autoimmune disorders. 3. Participants who smoke or have a history of heavy alcohol consumption. 4. Participants with dermatitis, open wounds, or skin infections in the periocular area. 5. Participants with a history of allergy to local anesthetics. 6. Participants with a history of hormonal therapy, injectable or oral contraceptives, or regular use of NSAIDs. 7. Participants who have received periocular filler injections or botulinum toxin within 6 months prior to study enrollment. 8. Participants who have undergone periocular lifting or tightening procedures within 6 months prior to study enrollment. 9. Participants with a history of keloid or hypertrophic scarring. 10. Participants with a psychiatric disorder diagnosed by a psychiatrist. 11. Participants who do not consent to standardized photography for treatment evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lateral canthal Height baseline, immediate, 1 week, 1 month, 3 months, and 6 months following treatment Vectra,Lateral eyebrow Height baseline, immediate, 1 week, 1 month, 3 months, and 6 months following treatment Vectra | — |
Secondary
| Measure | Time frame |
|---|---|
| Participants improvement scale immediate, 1 week, 1 month, 3 months, and 6 months following treatment Quartile scale,Safety immediate, 1 week, 1 month, 3 months, and 6 months following treatment Adverse events,Pain score at treatment Visual analog scale | — |
Countries
Thailand
Contacts
Public ContactThanya Techapichetvanich
Department of Dermatology, Faculty of Medicine Siriraj hospital, Mahidol university
Outcome results
None listed